
Nyeemah A. Grazier
Examiner (ID: 16340, Phone: (571)272-6256 , Office: P/1626 )
| Most Active Art Unit | 1626 |
| Art Unit(s) | PIA, 1626 |
| Total Applications | 843 |
| Issued Applications | 630 |
| Pending Applications | 26 |
| Abandoned Applications | 193 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 13251147
[patent_doc_number] => 10138252
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2018-11-27
[patent_title] => Lactones
[patent_app_type] => utility
[patent_app_number] => 16/101555
[patent_app_country] => US
[patent_app_date] => 2018-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4490
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 220
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16101555
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/101555 | Lactones | Aug 12, 2018 | Issued |
Array
(
[id] => 14087993
[patent_doc_number] => 10239888
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-03-26
[patent_title] => Targeted protein degradation using a mutant E3 ubiquitin ligase
[patent_app_type] => utility
[patent_app_number] => 16/045346
[patent_app_country] => US
[patent_app_date] => 2018-07-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 13
[patent_no_of_words] => 63476
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16045346
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/045346 | Targeted protein degradation using a mutant E3 ubiquitin ligase | Jul 24, 2018 | Issued |
Array
(
[id] => 13826475
[patent_doc_number] => 20190016722
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-17
[patent_title] => NOVEL SUBSTITUTED XANTHINE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/031399
[patent_app_country] => US
[patent_app_date] => 2018-07-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10324
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16031399
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/031399 | Substituted xanthine derivatives | Jul 9, 2018 | Issued |
Array
(
[id] => 13732869
[patent_doc_number] => 20180370902
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-27
[patent_title] => SOLABEGRON ZWITTERION AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/018945
[patent_app_country] => US
[patent_app_date] => 2018-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10202
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16018945
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/018945 | Solabegron zwitterion and uses thereof | Jun 25, 2018 | Issued |
Array
(
[id] => 14818343
[patent_doc_number] => 10406157
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-09-10
[patent_title] => Tetrahydropyridopyrazine modulators of GPR6
[patent_app_type] => utility
[patent_app_number] => 16/009308
[patent_app_country] => US
[patent_app_date] => 2018-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 14748
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16009308
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/009308 | Tetrahydropyridopyrazine modulators of GPR6 | Jun 14, 2018 | Issued |
Array
(
[id] => 13565797
[patent_doc_number] => 20180334446
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-22
[patent_title] => CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS
[patent_app_type] => utility
[patent_app_number] => 15/985168
[patent_app_country] => US
[patent_app_date] => 2018-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62871
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15985168
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/985168 | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | May 20, 2018 | Issued |
Array
(
[id] => 13507657
[patent_doc_number] => 20180305371
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-25
[patent_title] => NOVEL LACTONES
[patent_app_type] => utility
[patent_app_number] => 15/949124
[patent_app_country] => US
[patent_app_date] => 2018-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4473
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15949124
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/949124 | Lactones | Apr 9, 2018 | Issued |
Array
(
[id] => 13342671
[patent_doc_number] => 20180222875
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-09
[patent_title] => METHOD FOR PREPARING 2-MERCAPTOBENZOTHIAZOLE
[patent_app_type] => utility
[patent_app_number] => 15/948321
[patent_app_country] => US
[patent_app_date] => 2018-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2549
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15948321
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/948321 | Method for preparing 2-mercaptobenzothiazole | Apr 8, 2018 | Issued |
Array
(
[id] => 13314131
[patent_doc_number] => 20180208602
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-26
[patent_title] => NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 15/933790
[patent_app_country] => US
[patent_app_date] => 2018-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11740
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15933790
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/933790 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | Mar 22, 2018 | Abandoned |
Array
(
[id] => 13492809
[patent_doc_number] => 20180297947
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-18
[patent_title] => TRITIATED NITROXIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/912121
[patent_app_country] => US
[patent_app_date] => 2018-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5566
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15912121
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/912121 | Tritiated nitroxides and uses thereof | Mar 4, 2018 | Issued |
Array
(
[id] => 12880570
[patent_doc_number] => 20180185365
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-05
[patent_title] => Pharmaceutical Combinations
[patent_app_type] => utility
[patent_app_number] => 15/879942
[patent_app_country] => US
[patent_app_date] => 2018-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16044
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15879942
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/879942 | Pharmaceutical Combinations | Jan 24, 2018 | Abandoned |
Array
(
[id] => 13399881
[patent_doc_number] => 20180251483
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-06
[patent_title] => THIOCYANATE SALTS FOR ANTI-INFLAMMATION
[patent_app_type] => utility
[patent_app_number] => 15/782359
[patent_app_country] => US
[patent_app_date] => 2017-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13054
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15782359
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/782359 | THIOCYANATE SALTS FOR ANTI-INFLAMMATION | Oct 11, 2017 | Abandoned |
Array
(
[id] => 12769762
[patent_doc_number] => 20180148422
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-31
[patent_title] => FORMULATION OF METAXALONE
[patent_app_type] => utility
[patent_app_number] => 15/696125
[patent_app_country] => US
[patent_app_date] => 2017-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10092
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15696125
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/696125 | FORMULATION OF METAXALONE | Sep 4, 2017 | Abandoned |
Array
(
[id] => 12118692
[patent_doc_number] => 20180002277
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-04
[patent_title] => 'ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17'
[patent_app_type] => utility
[patent_app_number] => 15/615393
[patent_app_country] => US
[patent_app_date] => 2017-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 55
[patent_figures_cnt] => 55
[patent_no_of_words] => 47834
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15615393
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/615393 | Antioxidant Inflamation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | Jun 5, 2017 | Issued |
Array
(
[id] => 15468475
[patent_doc_number] => 10550100
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-02-04
[patent_title] => 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis
[patent_app_type] => utility
[patent_app_number] => 16/308380
[patent_app_country] => US
[patent_app_date] => 2017-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35367
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 485
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308380
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/308380 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | May 31, 2017 | Issued |
Array
(
[id] => 12766042
[patent_doc_number] => 20180147182
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-31
[patent_title] => Breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as active ingredient
[patent_app_type] => utility
[patent_app_number] => 15/595164
[patent_app_country] => US
[patent_app_date] => 2017-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6314
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15595164
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/595164 | Breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as active ingredient | May 14, 2017 | Issued |
Array
(
[id] => 14029475
[patent_doc_number] => 10226468
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-03-12
[patent_title] => Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways
[patent_app_type] => utility
[patent_app_number] => 15/581330
[patent_app_country] => US
[patent_app_date] => 2017-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 29613
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15581330
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/581330 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | Apr 27, 2017 | Issued |
Array
(
[id] => 12000124
[patent_doc_number] => 20170304279
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-26
[patent_title] => 'PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY'
[patent_app_type] => utility
[patent_app_number] => 15/496318
[patent_app_country] => US
[patent_app_date] => 2017-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 29612
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15496318
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/496318 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | Apr 24, 2017 | Issued |
Array
(
[id] => 11948175
[patent_doc_number] => 20170252326
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-07
[patent_title] => 'COMPOSITIONS AND METHODS OF INHIBITING METALLO-BETA-LACTAMASES'
[patent_app_type] => utility
[patent_app_number] => 15/463952
[patent_app_country] => US
[patent_app_date] => 2017-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 19026
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15463952
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/463952 | Compositions and methods of inhibiting metallo-b-lactamases | Mar 19, 2017 | Issued |
Array
(
[id] => 11690852
[patent_doc_number] => 20170166567
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-06-15
[patent_title] => 'IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS'
[patent_app_type] => utility
[patent_app_number] => 15/443349
[patent_app_country] => US
[patent_app_date] => 2017-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18842
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15443349
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/443349 | IMIDAZO[4,5-C]QUINOLINES AS DNA-PK INHIBITORS | Feb 26, 2017 | Abandoned |